Total Payments
$241,174
2024 Payments
$14,014
Companies
13
Transactions
114
Medicare Patients
4,005
Medicare Billing
$345,108
Payment Breakdown by Category
Consulting$204,172 (84.7%)
Other$31,800 (13.2%)
Travel$2,912 (1.2%)
Food & Beverage$2,163 (0.9%)
Education$126.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,172 | 52 | 84.7% |
| Grant | $25,000 | 1 | 10.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,800 | 4 | 2.8% |
| Travel and Lodging | $2,912 | 8 | 1.2% |
| Food and Beverage | $2,163 | 46 | 0.9% |
| Education | $126.40 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Solta Medical, a division of Bausch Health US, LLC | $141,749 | 36 | $0 (2024) |
| Allergan, Inc. | $68,311 | 46 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $25,125 | 2 | $0 (2017) |
| Galderma Laboratories, L.P. | $2,492 | 5 | $0 (2022) |
| ABBVIE INC. | $2,011 | 6 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $967.73 | 2 | $0 (2017) |
| LEO Pharma Inc. | $154.43 | 6 | $0 (2022) |
| Astellas Pharma US Inc | $112.39 | 2 | $0 (2021) |
| REVANCE THERAPEUTICS, INC. | $109.02 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $55.00 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,014 | 17 | Solta Medical, a division of Bausch Health US, LLC ($13,458) |
| 2023 | $15,181 | 4 | Solta Medical, a division of Bausch Health US, LLC ($13,558) |
| 2022 | $18,146 | 15 | Allergan, Inc. ($10,922) |
| 2021 | $31,053 | 16 | Allergan, Inc. ($16,491) |
| 2020 | $22,921 | 8 | Solta Medical, a division of Bausch Health US, LLC ($22,010) |
| 2019 | $70,557 | 19 | Solta Medical, a division of Bausch Health US, LLC ($69,984) |
| 2018 | $3,536 | 4 | Solta Medical, a division of Bausch Health US, LLC ($3,480) |
| 2017 | $65,766 | 31 | Allergan Inc. ($39,485) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Consulting Fee | Cash or cash equivalent | $6,960.00 | General |
| 11/12/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $23.79 | General |
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $12.68 | General |
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $4.90 | General |
| 10/17/2024 | Solta Medical, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $0.40 | General |
| 10/16/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Travel and Lodging | In-kind items and services | $280.12 | General |
| 10/16/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Food and Beverage | In-kind items and services | $96.62 | General |
| 10/16/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Food and Beverage | In-kind items and services | $31.87 | General |
| 10/16/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Food and Beverage | In-kind items and services | $11.98 | General |
| 10/16/2024 | Solta Medical, a division of Bausch Health US, LLC | THERMAGE FLX | Food and Beverage | In-kind items and services | $8.20 | General |
| 09/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: Immunology | ||||||
| 08/10/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $347.00 | General |
| 08/07/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $68.16 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 07/22/2024 | Novartis Pharmaceuticals Corporation | XOLAIR (Drug) | Food and Beverage | In-kind items and services | $34.41 | General |
| Category: Pulmonary/Respiratory Diseases | ||||||
| 07/09/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 03/26/2024 | Solta Medical, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $6,069.00 | General |
| 01/31/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 10/27/2023 | Solta Medical, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $7,902.50 | General |
| 09/13/2023 | AbbVie Inc. | — | Education | In-kind items and services | $8.45 | General |
| 08/13/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $1,614.61 | General |
| 01/05/2023 | Solta Medical, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $5,655.00 | General |
| 12/13/2022 | Solta Medical, a division of Bausch Health US, LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 10/12/2022 | Allergan, Inc. | BOTOX (Biological) | Consulting Fee | Cash or cash equivalent | $415.33 | General |
| Category: FACIAL AESTHETICS | ||||||
| 10/04/2022 | Allergan, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,560.00 | General |
| 09/14/2022 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,303 | 2,356 | $415,668 | $111,963 |
| 2022 | 12 | 1,019 | 1,730 | $230,240 | $89,138 |
| 2021 | 13 | 968 | 1,985 | $222,645 | $86,541 |
| 2020 | 10 | 715 | 1,288 | $167,214 | $57,465 |
Total Patients
4,005
Total Services
7,359
Medicare Billing
$345,108
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 365 | 510 | $129,540 | $34,913 | 27.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 190 | 246 | $81,396 | $24,141 | 29.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 183 | 256 | $51,784 | $11,388 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 95 | 109 | $38,285 | $10,444 | 27.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 85 | 93 | $25,830 | $6,839 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 71 | 71 | $22,540 | $6,230 | 27.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 144 | 849 | $20,376 | $5,020 | 24.6% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 25 | 33 | $16,344 | $4,997 | 30.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 68 | 81 | $13,155 | $3,695 | 28.1% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 17 | 17 | $5,550 | $1,517 | 27.3% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 15 | 29 | $5,100 | $1,218 | 23.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 17 | 19 | $2,748 | $878.36 | 32.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 13 | 13 | $2,930 | $655.77 | 22.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 30 | $90.00 | $25.17 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 292 | 405 | $60,750 | $28,381 | 46.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 167 | 207 | $52,164 | $19,870 | 38.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 149 | 191 | $32,852 | $9,054 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 86 | $18,490 | $8,464 | 45.8% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 31 | 40 | $13,760 | $5,978 | 43.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 53 | 53 | $12,720 | $4,244 | 33.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 47 | 48 | $10,080 | $3,799 | 37.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 110 | 550 | $13,200 | $3,437 | 26.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 58 | 67 | $7,035 | $2,931 | 41.7% |
| 10060 | Simple or single drainage of skin abscess | Office | 2022 | 18 | 19 | $4,750 | $1,636 | 34.4% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2022 | 15 | 31 | $4,340 | $1,318 | 30.4% |
About Dr. Jeffrey Dover, MD
Dr. Jeffrey Dover, MD is a Dermatology healthcare provider based in Chestnut Hill, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316909005.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Dover, MD has received a total of $241,174 in payments from pharmaceutical and medical device companies, with $14,014 received in 2024. These payments were reported across 114 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($204,172).
As a Medicare-enrolled provider, Dover has provided services to 4,005 Medicare beneficiaries, totaling 7,359 services with total Medicare billing of $345,108. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Chestnut Hill, MA
- Active Since 04/06/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1316909005
Products in Payments
- RHOFADE (Drug) $10,253
- THERMAGE FLX $7,389
- BOTOX (Biological) $1,776
- XIAFLEX (Biological) $967.73
- BOTOX COSMETIC (Biological) $504.69
- DAXXIFY (Drug) $109.02
- ADBRY (Biological) $80.19
- ENSTILAR (Drug) $74.24
- XOLAIR (Drug) $34.41
- Otezla (Drug) $25.15
- DUPIXENT (Biological) $23.68
- DUPIXENT (Drug) $22.50
- COSENTYX (Biological) $20.59
- TALTZ (Drug) $14.39
- LEXISCAN (Drug) $12.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Chestnut Hill
Jeffrey Sobell, Md, MD
Dermatology — Payments: $1.2M
Dermatology $1.2M
Michael Kaminer, Md, MD
Dermatology — Payments: $1.1M
Dermatology $1.1M
Kenneth Arndt, Md, MD
Dermatology — Payments: $38,802
Dermatology $38,802
Dr. Brooke Sikora, M.d, M.D
Dermatology — Payments: $26,039
Dermatology $26,039
Thomas Rohrer, M.d, M.D
Dermatology — Payments: $12,331
Dermatology $12,331
Robin Travers, Md, MD
Dermatology — Payments: $7,746
Dermatology $7,746